ARA 290 (Cibinetide) is an 11-amino acid synthetic peptide derived from the B-helix surface of erythropoietin that selectively activates the Innate Repair Receptor (IRR) without triggering erythropoiesis.
Scientific Profile & Research Key Points: ARA 290
ARA 290 (Cibinetide) is an 11-amino acid synthetic peptide derived from the B-helix surface of erythropoietin that selectively activates the Innate Repair Receptor (IRR) without triggering erythropoiesis.
Active Batch Release Specifications (Lot SL-2026-107)
Analytical release verification for current ARA 290 (16 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-107 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile PBS (pH 7.4) or sterile 0.9% Bacteriostatic Water
Temperature & Stability
Store lyophilized vial at -20°C dry; refrigerate reconstituted solutions at 2°C–8°C for up to 21 days.
ARA 290 — Technical Questions & Answers
What is the molar concentration when reconstituting ARA 290 (16 mg) in 2.0 mL?
Reconstituting the full 16 mg vial of ARA 290 (MW 1257.31 g/mol) in 2.0 mL of diluent produces a 8.00 mg/mL stock solution — equivalent to approximately 6.36 mM (6,363 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does ARA 290's counterion stoichiometry affect assay mass calculations?
ARA 290 (CAS 1208243-50-8, formula C51H84N16O21) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify ARA 290 Lot SL-2026-107 and what pathway does it target?
Lot SL-2026-107 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 1257.31 g/mol. In preclinical literature, ARA 290 targets Innate Repair Receptor (EPOR / β-common receptor heteromer) (Brines M. et al., Proc Natl Acad Sci USA (2008) — Non-erythropoietic helix-B surface peptide activating the innate repair receptor (PMID: 18676614)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
Selank vs Semax: Comparative Heptapeptide Chemistry, BDNF Upregulation, and GABAergic Modulation
A structural and pharmacological comparison of Russian-developed regulatory heptapeptides: Semax (ACTH 4-10 analogue) vs Selank (Tuftsin analogue). Molecular pathways and stability.
ARA-290 (Cibinetide): Non-Erythropoietic Tissue Protection, Innate Repair Receptor (IRR) Activation, and Neuropathy Models
A molecular study of the erythropoietin-derived peptide ARA-290 (Cibinetide). Selective activation of the Innate Repair Receptor (EPOR/CD131), suppression of microglial activation, and nerve regeneration.
How to Read a Peptide Certificate of Analysis (COA): Step-by-Step Breakdown
A practical guide for researchers. How to analyze HPLC chromatograms, verify retention time, interpret mass spec m/z peaks, evaluate counterion salt ratios, and spot fraudulent documents.
Related Recovery & Tissue Repair Compounds
View category →